In the Study of Anastrozole with the Bisphosphonate Risedronate (SABRE) trial, oral risedronate 35 mg once weekly was assessed in post‐menopausal women with hormone receptor‐positive early breast cancer undergoing adjuvant anastrozole therapy, stratified by fracture risk. The gene discussed is NR4A1; the disease is breast carcinoma.